Tasigna® International Patient Assistance Program (TIPAP)
Novartis Oncology has expanded its patient access programs to incorporate Tasigna® (nilotinib), a potent and selective inhibitor of the Bcr-Abl protein that causes production of cancer cells in the Philadelphia chromosome- positive chronic myeloid leukemia (Ph+ CML)
In countries where full donation is the only appropriate path to access to Tasigna, Novartis, in partnership with The Max Foundation, has begun to establish TIPAP to ensure that patients can receive this valuable medication.
Full donation of Tasigna through TIPAP will be available to Glivec patients who meet both clinical and economic criteria. Leading experts in CML around the world have developed and published medical criteria to determine when it is appropriate to prescribe Tasigna for particular patients. Economic eligibility for full donation of medicine through TIPAP is consistent with criteria employed for GIPAP.
New access models will facilitate partial donation of Tasigna to other patients in countries where full donation is not applicable.